Gilead to acquire Arcellx for $7.8B

Kite Pharma (Gilead)/Anito-cel (anitocabtagene autoleucel)

Gilead to acquire Arcellx for $115/share plus $5 CVR, totaling $7.8B. Closes Q2 2026 to gain full control of anito-cel and enable exploration in earlier MM lines.

• $115/share + $5 CVR = $7.8B equity value
• Q2 2026 close; Arcellx becomes subsidiary
• Eliminates profit-sharing; full development control
• BLA Dec 23, 2026 PDUFA for fourth-line MM
• Plans for earlier treatment lines and in vivo therapies